Palisade Bio Inc (PALI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $201.01M
Last updated: Nov 17, 2026 at 4:15 PM ET
Palisade Bio Inc (PALI) Statistics
Palisade Bio (PALI) has a market cap of $201.01M and an enterprise value of $87.40M. Its share count is up 2736.91% from a year earlier. Revenue grew 12400.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 56.52% below the market cap, as cash exceeds debt.
| Market Cap | $201.01M |
|---|---|
| Enterprise Value | $87.40M |
| Latest price (Nov 17, 2026) | $1.01 |
Key Dates
The next earnings report is expected on Mar 18, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 18, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 428.3x and 1.9x.
| P/S Ratio | 428.3x |
|---|---|
| Forward P/S | 402.0x |
| P/B Ratio | 1.9x |
Price Statistics
The stock is down 52.80% over 52 weeks and trades 29.37% below its 50-day average.
| Beta (1Y) | 1.25 |
|---|---|
| 52-Week Change | -52.80% |
| 1-Month Change | -24.63% |
| 3-Month Change | -53.24% |
| 6-Month Change | -44.20% |
| 5-Year Change | -99.94% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -52.80% |
| Total Return (3Y CAGR) | -51.89% |
| Total Return (5Y CAGR) | -77.49% |
| Return vs SPY (1Y) | -62.77% |
| Max Drawdown (1Y) | -63.93% |
| Max Drawdown (3Y) | -96.26% |
| Sharpe Ratio (1Y) | -0.82 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $1.43 |
| 200-Day Average | $1.82 |
| 52-Week Range | $1.01 to $2.86 |
| RSI (14 Days) | 31.6 |
| Average Volume (20 Days) | 3.69M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 20.16x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 20.16x |
|---|---|
| Quick Ratio | 20.16x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -38.86% and return on assets is -36.86% over the last 12 months.
| Return on Equity (ROE) | -38.86% |
|---|---|
| Return on Assets (ROA) | -36.86% |
| Return on Capital Employed (ROCE) | -38.76% |
| ROIC (5Y Average) | -10.23% |
| Asset Turnover | 0.01x |
| Receivables Turnover | 2.00x |
Scores
PALI has an Altman Z-Score of 18.75, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 18.75 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $500.00K over the last 12 months.
| Revenue | $500.00K |
|---|---|
| Revenue Growth (YoY) | +12400.00% |
| Operating Income | -$48.13M |
| Pretax Income | -$43.70M |
| Net Income | -$43.70M |
| EBITDA | -$43.69M |
| EBIT | -$43.69M |
| Reported EPS (TTM) | -$0.22 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 94.85% of the $118.55M in total assets.
| Cash and Equivalents | $113.61M |
|---|---|
| Total Debt | $0 |
| Net Cash | $113.61M |
| Net Cash Per Share | $0.54 |
| Working Capital | $111.65M |
| Shareholder Equity | $112.44M |
| Book Value Per Share | $0.53 |
| Total Assets | $118.55M |
| Total Liabilities | $6.11M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$26.40M |
|---|---|
| FCF Per Share | -$0.15 |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -9625.40%.
| Operating Margin | -9625.40% |
|---|---|
| Pretax Margin | -8739.20% |
| Net Margin | -8739.20% |
| EBITDA Margin | -8738.60% |
| EBIT Margin | -8738.60% |
Dividends and Yields
PALI does not pay a dividend.
| Buyback Yield | -61.26% |
|---|---|
| Shareholder Yield | -61.26% |
Stock Splits
The last split was a 1-for-15 reverse split on Apr 8, 2024.
| Last Split Date | Apr 8, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Peer Position
Against 9 similar companies, PALI has the 2nd highest P/S.
P/S RatioPeer median 19.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -57.30%
| P/S Ratio | 428.3x vs 19.1x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +12400.00% vs -57.30% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PALI
What is PALI's market cap?
Palisade Bio has a market cap of $201.01M. Its enterprise value, which adds debt and subtracts cash, is $87.40M.
How many shares of PALI are outstanding?
Palisade Bio has 212.03M shares outstanding. The count is up 2736.91% from a year earlier.
Does PALI pay a dividend?
No. Palisade Bio does not pay a dividend.
How much debt does PALI have?
Palisade Bio has $0 of total debt and $113.61M of cash and equivalents, a net cash position of $113.61M.
PALI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors